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Terus Hidup Dan Status Prestasi Setahun Dalam Pesakit Dewasa Sepsis, Sepsis, 
Sepsis Teruk Dan Kejutan Sepsis  
ABSTRAK 
Sepsis adalah punca utama morbiditi dan kematian. Pengiktirafan kesan jangka 
panjang dalam penyakit kritikal yang terselamat telah beralih nilai hasil daripada 
pengurangan kematian di hospital ‘ke hasil berpusatkan pesakit’ yang berkaitan 
kesihatan  ia-itu kualiti penghidupan (HR-QOL). Data yang terhad berkaitan  kesan  
susualan  jangka panjang susulan pesakit sepsis teruk dan kejutan septik (SS & SK) 
yang terselamat. Oleh itu, objektif kajian ini adalah untuk mendapatkan siapa yang 
mampu untuk terus hidup berbanding bukan hidup dan untuk memastikan status 
prestasi mereka se tahun selepas keluar-hospital, bergikut melawan masa dan faktor-
faktor ramalan. 
Kajian  kohort retrospektif  dan keratan rentas yang dijalankan kepada pesakit 
dewasa (≥ 18 tahun) yang telah dimasukkan ke ICU perubatan- pembedahan dan 
trauma  di hospital penjagaan tertiary sekurang-kurangnya 24 jam diantara April 
2007 hingga Mac 2010. Hanya pesakit yang masih hidup pada masa pelepasan 
hospital telah dipilih. Pesakit yang masih hidup ditemuramah melalui telefon untuk 
menentukan status prestasi mereka setahun selepas keluar-hospital menggunakan 
"Karnofsky prestasi status skala". 
Daripada 524 kes, hanya 195 kes memenuhi kriteria yang termasuk. Kira-kira satu 
pertiga daripada 195 pesakit-pesakit SS & SK telah meninggal. Satu pertiga 
menderita kemerosotan prestasi yang ketara (tidak dapat bekerja serta tidak mampu 
untuk menjaga diri-sendiri), dan hanya satu pertiga dapat bekerja semasa setahun 
selepas keluar-hospital. 
xxiv 
 
Kematian meningkat berkadaran dengan masa dalam masa setahun keluar-hospital 
dan lebih daripada separuh kematian  berlaku dalam masa tiga bulan  selepas keluar-
hospital.  Status prestasi pra-sepsis dan berpenyakit CHF mempergaruhi hasil-hasil   
prestasi dan  masih hidup yang ketara  selepas  keluar–hospital, terutamanya pesakit 
tua (≥ 65 tahun). Pesakit yang status prestasi terjejas semasa pra-sepsis, risiko 
kematian meningkat tiga kali ganda berbanding dengan mereka yang mampu bekerja 
semasa pra-sepsis. Selain itu, pesakit yang mampu untuk menjalankan aktiviti biasa 
dan bekerjasemasa pra-sepsis adalah lebih mampu untuk terus hudip dalam tempoh 
setahun selepas keluar-hospital. 
Kesimpulannya, kematian telah meningkat dengan masa dalam tempoh setahun 
selepas keluar-hospital. Status prestasi dan berpenyakit CHF adalah faktor-faktor  
penting  yang mempengaruhi hasil-hasil  untuk mampu terus hidup dan prestasi 
dalam pesakit-pesakit SS & SK selepas keluar-hospital. Data ini menonjolkan 
kumpulan–kumpulan pesakit sepsis yang perlu diberikan lebih perhatian. 
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One-Year Survival and Performance status in Adult Patients with Sepsis, 
Severe Sepsis, and Septic Shock 
ABSTRACT 
Sepsis, based on a number of researches, is considered a significant cause of 
morbidity and mortality. Recognition of long-term sequelae in survivors from critical 
illnesses has shifted the outcome values from reduction in hospital mortality to 
‘patient centered outcomes’, such as health related quality of life (HR-QOL). There 
is limited data available on long-term follow-up survivors with severe sepsis and 
septic shock (SS & SK). Therefore, the objectives of this study were to determine 
who were able to survive versus those unable to survive for one-year post-hospital 
discharge and to ascertain their performance status, survival versus time post 
discharge and prognostic factors. 
A retrospective cohort and cross-sectional study was conducted in relation to adult 
patients (≥18 years) who were admitted to the medical-surgical and trauma ICU of a 
tertiary care hospital, at least 24 hours during the period between April 2007 and 
March 2010. The patients selected were the ones who were still alive at the time of 
hospital discharge. Survivors were interviewed on the telephone to determine their 
performance status after one-year of their hospital discharge using “Karnofsky 
performance status scale”.  
Among the 524 cases of patients assessed, only 195 cases were included based on 
inclusion criteria.  Around one-third of the 195 SS & SK survivors died. Another 
one-third suffered significant impairment of performance status (unable to work plus 
or even care for self). It was also observed that only one third of these cases were 
able to work for one-year after being hospital discharged. 
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The mortality rate increased with time throughout the first year of patient’s post-
hospital discharge. However, more than half of the death cases occurred within the 
first three months of post hospital discharge. Pre-sepsis performance status and pre-
existing CHF significantly affects the outcomes and duration of the survival of post-
hospital discharged patients, particularly in elderly survivors (≥ 65 years). The risk of 
death for patients who had impaired pre-sepsis performance status increased three 
times more when compared to those who were able to work during their pre-sepsis 
status. Furthermore, the rate of survival among patients able to carry out normal 
activity and work during pre-sepsis was much higher during the one year post 
hospital discharge.  
In conclusion, the mortality was increasing with time within one-year of post-
hospital discharge. Pre-sepsis performance status and pre-existing CHF are important 
factors affecting the survival and performance outcomes in post hospital discharge 
SS & SK cases. This data highlights the need for more intensive attention for the 
groups of sepsis survivors. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background and definitions 
 “Sepsis” as a word originally comes from the Greek word “sepo”, which means decay 
or putrefaction, and the original usage of this word described the decomposition of 
organic matter in a manner that resulted in decay and death (Geroulanos et al., 2006). In 
the Hippocratic model of health and disease, living tissues broke down by one of two 
processes. “Pepsis” was the process through which food was digested, leading to health. 
Sepsis, however, denoted tissue breakdown that resulted in disease. Hippocrates used 
this term to describe the process of abnormal tissue breakdown that resulted in a foul 
odour, pus-formation, and sometimes-dead tissue (Vincent et al., 2006). This usage of 
the term sepsis persisted for almost 3 millennia, and subsequent work establishing a 
causal link between microbes and suppurative infections, or systemic symptoms from 
infection, did not change the use of the term as a description of a constellation of 
clinical findings, but rather established infection as the underlying cause (Schottmueller, 
1914) The term “shock” comes from the French word "choquer meaning “to collide 
with,” and aptly describes the body’s response to invading microbes and, to a large 
extent, its disruptive effect on normal physiology. It was used in the medical literature 
initially in the 1700s; its earliest uses connoted a sudden jolt that often led to death (the 
initial physical injury). This definition evolved to describe widespread circulatory 
dysfunction following injury (Cannon, 1923; Nduka et al., 2011) 
Sepsis is the systemic maladaptive response of the body to the invasion of normally 
sterile tissue by pathogenic, or potentially pathogenic, microorganisms. Shock may be 
defined as a “state in which profound and widespread reduction of effective tissue 
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perfusion leads first to reversible, and then, if prolonged, to irreversible cellular injury.” 
(Kumar & Parrillo, 2008). From a clinical standpoint, this progressive cellular 
dysfunction manifests as a continuum from sepsis, to severe sepsis, and finally to septic 
shock (Nduka et al., 2011) as shown in (Figure 1.1 and Figure 1.2). 
Sepsis syndrome results from a host reaction to infection, which includes a robust 
systemic inflammatory response, enhanced coagulation, and impaired fibrinolysis (Bone 
et al. 1992; Hotchkiss et al., 2003). The systemic inflammatory response syndrome 
(SIRS) is defined by the constellation of fever or hypothermia, tachycardia, tachypnea, 
and leukocytosis, leukopenia, or the presence of immature neutrophils. SIRS can result 
from numerous conditions but only becomes ‘‘sepsis’’ when infection is etiologic. 
When sepsis causes at least one organ dysfunction, the syndrome is termed ‘‘severe 
sepsis,’’ and sepsis-induced hypotension that is refractory to fluid challenge defines 
‘‘septic shock’’ (Table 1.1). While the SIRS criteria are sensitive for septic patients, the 
investigators criticized it for lacking specificity. Many, if not most, of ICU patients have 
tachypnea and tachycardia, this raising doubt about the diagnostic utility of the SIRS 
criteria (Vincent, 1997). Although the specificity of SIRS is increased by requiring two 
or more of the criteria or by mandating that one of two required criteria is abnormal 
temperature or white blood cell count. (Bone et al., 1992; Marshall  et al., 1995; Brun-
Buisson, 2000; Levy et al., 2003; Dellinger et al., 2004; Lin SM et al., 2004; Poze et 
al., 2004; Emanuel et al., 2005; Martin et al., 2009) 
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Figure 1.1: The relationship of infection, SIRS, severe sepsis, and sepsis. (Adapted 
from, Bone RC et al. Definitions for sepsis and organ failure and guidelines for the use of innovative 
therapies in sepsis. Chest 1992; 101:1644-55)  
 
Figure 1.2: Pathogenic mechanisms from infection to septic shock. The initial response 
to an infecting organism is a systemic response, with release of inflammatory mediators and activation of 
the coagulation cascade. Microvascular injury, thrombosis, and diffuse endothelial disruption follow, 
resulting in imbalance between oxygen delivery and oxygen consumption. Global tissue hypoxia and 
cytopathic (cellular) hypoxia develop, leading to multiple organ dysfunction and irreversible shock 
(Adapted from, Nguyen,  et al. (2006). Severe Sepsis and Septic Shock: Review of the Literature and 
Emergency Department Management Guidelines. Ann Emerg Med, 48, 28-54. With permission from 
corresponding author)  
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Table 1.1: Sepsis definitions (Astiz et al., 1987; Rivers, Nguyen et al., 2001; Emanuel 
et al., 2005) 
Sepsis definitions 
Systemic inflammatory response syndrome (SIRS)-includes two or more of:  
 Temperature > 38º or < 36º C 
 Heart rate > 90 beat/min. unless the patient is taking medications to reduce 
the rate (a beta-blocker or calcium-channel blocker) or the heart is paced. 
 Respiratory rate > 20 breaths/min (or PaCo2 < 32 torr) or mechanically 
ventilated 
 Leukocyte count > 12000/µL or < 4000/ µL or > 10% immature band forms. 
 
Sepsis 
 Presence or presumed presence of an infection accompanied by evidence of 
SIRS 
 
Severe sepsis: presence of sepsis, plus organ hypoperfusion or dysfunction 
 Organ hypoperfusion; for example:   
o Increased blood lactate levels 
o Oliguria 
o Abnormal peripheral circulation, such as poor capillary refill, mottled 
skin 
o Acute alteration in mental status 
 Dysfunction* of one or more organs, such as abnormalities of: 
o The hematologic system; e.g. thrombocytopenia, disseminated 
intravascular coagulation 
o The pulmonary system; e.g., acute respiratory distress syndrome 
o The renal system; e.g., acute renal failure 
o The gastrointestinal system with hepatic dysfunction; e.g. 
hyperbilirubinemia 
o The central nervous system; e.g., delirium 
 
Septic shock† 
 Presence of sepsis 
 Refractory hypotension: 
o Systolic blood pressure < 90 mm Hg 
o A mean arterial pressure < 65 mm Hg, or a 40 mm Hg drop in systolic 
blood pressure compared to baseline. 
o Unresponsive to a fluid challenge of 20-40 mL/kg 
 Vasopressor dependency after adequate volume resuscitation 
*Organs considered to have failed when the organ dysfunction becomes most severe. 
†Note that this is a standard definition. It is important to recognize that a patient may be in septic shock 
with a normal blood pressure if the baseline blood pressure is elevated (e.g., someone with a history of 
hypertension, diabetes or vascular disease) or there is concomitant myocardial dysfunction. 
Adapted from, Emanuel, P. R., Lauralyn, M., David, C. M., & Kandis, K. R. (2005). Early and innovative 
interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ, 
173(9), 1054-65. (Reprinted with permission from, the corresponding author and publisher “Access 
Copyright, the Canadian copyright licensing agency”). 
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1.1.1 Previous and current definitions of sepsis 
The previous history of sepsis word is derived from ‘‘sepo’’ which originally a 
Greek word used for the decomposition of animal or vegetable organic matter 
(Geroulanos et al., 2006). Homer was the first one who used the word  “Sepsis” since 
more than 2700 years ago, and the link between bacteria and systemic signs of disease 
was made around 100 years ago (Schottmueller, 1914). Later "sepsis” became almost 
synonymous with severe infection. More recently, as the role of the immune response 
has become clearer, we have realized that what we had called sepsis is in fact a host 
response to the invading microorganism rather than any specific feature of the 
microorganism itself. Indeed, sepsis can be initiated by any microorganism, whether it 
is bacterial, fungal, viral, parasitic, or by microbial products and toxins, and is then 
propagated by a complex network of inflammatory mediators and cellular dysfunction. 
Sepsis is a syndrome and one of the first attempts to establish a set of clinical 
parameters to define patients who have severe sepsis came in 1989 when Roger Bone 
and colleagues (Bone et al., 1992) proposed the term ‘‘sepsis syndrome’’. Sepsis 
syndrome was defined as hypothermia (less than 96 F [35.5 C]) or hyperthermia (greater 
than 101 F [38.3 C]); tachycardia (greater than 90 beat/min); tachypnea (greater than 20 
breath/min); clinical evidence of an infection site; and the presence of at least one end-
organ demonstrating inadequate perfusion or dysfunction expressed as poor or altered 
cerebral function, hypoxemia (PaO2 less than 75 torr on room air), elevated plasma 
lactate, or oliguria (urine output less than 30 mL/h or 0.5 mL/kg body weight/h without 
corrective therapy). However, although it has been used as an entry criterion for clinical 
trials (Bone et al., 1992; Panacek et al., 2004) sepsis syndrome does not successfully 
define a homogeneous group of patients.  
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Therefore, the American college of chest physicians (ACCP) and the society of critical 
care medicine (SCCM) convened a consensus conference in 1991 in an attempt to create 
a set of standardized definitions (ACCP-SCCM consensus conference, 1992). 
Thirty-five experts in the field of sepsis were gathered together to provide a framework 
to define the systemic inflammatory response to infection (i.e., sepsis). The result of this 
conference was the introduction of the term ‘‘systemic inflammatory response 
syndrome’’ (SIRS). It had been recognized for some time that the same inflammatory 
response to infection could also occur in response to other conditions, including acute 
pancreatitis, trauma, ischemia/reperfusion injury, and burns. SIRS was an attempt to 
differentiate sepsis from these non-infectious causes. According to the ACCP-SCCM 
consensus conference, infection defined as a microbial phenomenon characterized by 
the invasion of microorganisms or microbial toxins into normally sterile tissues. SIRS is 
defined, by consensus, as the presence of at least two of four clinical criteria: 
1. Body temperature >38 C or <36 C 
2. Heart rate >90 beats/min 
3. Respiratory rate >20 breaths/min or hyperventilation with a PaCO2 <32 mmHg 
4. White blood cell count WBC >12,000/mm3, <4000/mm3, or with >10% 
immature neutrophils 
SIRS represent a systemic inflammatory response of any etiology, including sepsis, 
which is therefore defined by the presence of SIRS in association with a confirmed 
infection. Sepsis associated with organ dysfunction, hypoperfusion abnormality, or 
sepsis-induced hypotension is called severe sepsis, and septic shock is defined as severe 
sepsis with sepsis-induced hypotension persisting despite adequate fluid resuscitation. 
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The SIRS approach has been rapidly adopted and widely used to define populations of 
patients in interventional clinical trials. Trzeciak and colleagues (Trzeciak et al., 2005) 
reported that 69% of clinical trials in sepsis published between 1993 and 2001 used the 
consensus conference definitions. Similarly, Veloso and colleagues (Veloso et al., 2009) 
reported that 10 of the 11 multicenter, randomized controlled trials of new therapeutic 
interventions in adult patients who had severe sepsis published between January 2000 
and December 2007, used SIRS as part of the entrance criteria. Nevertheless, in the 
survey of 1058 physicians, including 529 intensives, conducted by Poeze and colleagues 
in 2000, only 5% (22% of the intensivists) gave the ACCP/SCCM definition when 
asked to define sepsis. Although the SIRS criteria do have the prognostic value of 
defining a group of patients who are at an increased risk of developing complications 
and with increased mortality (Napolitano et al., 2000; Malone et al., 2001; Sprung et al., 
2006) they have been criticized for being too sensitive and nonspecific to be of much 
clinical use ( Vincent, 1997). Most ICU patients and many general ward patients meet 
the SIRS criteria (Pittet et al., 1995; Rangel et al., 1995). In the sepsis occurrence in 
acutely ill patients study, 93% of ICU admissions had at least two SIRS criteria at some 
point during their ICU stay. 
Moreover, each of the SIRS criteria can be present in many different conditions, so that 
a label of SIRS provides little or no information about the underlying disease process. 
For example, fever can be present in sepsis, but also after myocardial infarction, 
pulmonary embolism, or postoperatively; tachycardia and tachypnea may be present in 
heart failure, anemia, respiratory failure, hypovolemia, sepsis, and so forth; a raised 
white blood cell count can be present in many diseases encountered in ICU patients, 
including trauma, heart failure, pancreatitis, hemorrhage, and pulmonary edema. The 
use of the SIRS criteria to define septic shock was also unrealistic. Any type of shock is 
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associated with hyperventilation (to compensate for the lactic acidosis), tachycardia 
(either to compensate for a decreased stroke volume or to achieve a supranormal cardiac 
output), and an increased white blood cell count (as part of the stress response). The 
body temperature is often within the normal range in septic shock. Accordingly, the 
SIRS criteria cannot separate septic from other types of shock. Furthermore, patients 
who meet the SIRS criteria have a wide range of disease severity, and hence, likely 
mortality. Use of the SIRS criteria to identify patients for enrolment in clinical trials has 
been disappointing, and has likely contributed to the negativity of almost all these trials. 
Indeed, use of SIRS for entrance into clinical trials generates a very heterogeneous 
group of patients with multiple underlying pathologies and disease severity; while some 
patients in such a mixed population may well benefit from the intervention, it is likely 
that others will not, thus diluting out any beneficial effect (Vincent et al., 2009). 
In 2001 Sepsis definitions conference with advances in our understanding of sepsis 
pathogenesis and pathophysiology and with continued dissatisfaction with available 
definitions of sepsis, a consensus sepsis definitions conference of 29 international 
experts in the field of sepsis was convened under the auspices of SCCM, the European 
Society of Intensive Care Medicine, ACCP, and the surgical infection societies (Levy et 
al., 2003). The conference participants concluded that the definitions of sepsis, severe 
sepsis, and septic shock, as defined in the 1991 North American consensus conference, 
might still be useful in clinical practice and for research purposes. The key change was 
in the use of the SIRS criteria, which considered too sensitive and nonspecific. The 
participants suggested that other signs and symptoms added to better reflect the clinical 
response to infection (Table 1.2). Sepsis is now defined as the presence of infection plus 
some of the listed signs and symptoms of sepsis. Severe sepsis is now defined as sepsis 
complicated by organ dysfunction and septic shock is defined as severe sepsis with 
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acute circulatory failure characterized by persistent arterial hypotension unexplained by 
other causes. Importantly, the list of signs of sepsis is meant as a guide, not all patients 
who have sepsis will have all the signs and symptoms listed, and many patients who do 
not have sepsis will have several of them. In addition, the list will change as new 
biomarkers are identified. These signs of sepsis should be considered as alarm signals 
that suggest the possibility of an infection and when combined with microbiological 
results and other evidence of organ involvement, can help in decisions regarding the 
need for antibiotics. (Klein Klouwenberg et al., 2012). 
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Table: 1.2: 2001-Sepsis definitions (Vincent,  Martinez & Silva, 2009) 
Move from 1991 systemic inflammatory response syndrome criteria to 
expanded list of signs and symptoms in 2001-sepsis definitions conference 
SIRS criteria: 
 Fever/hypothermia 
 Tachycardia 
 Tachypnea 
 Altered white blood cell count 
 
 
 
Sepsis definitions conference 2001: 
General signs and symptoms 
 Fever/hypothermia 
 Tachypnea/respiratory alkalosis 
 Positive fluid balance/edema 
 
General inflammatory reaction 
 Altered white blood cell count 
 Increased biomarker (C-reactive protein (CRP), IL-6, PCT) concentrations 
Hemodynamic alterations 
 Arterial hypotension 
 Tachycardia 
 Increased cardiac output/low systemic vascular resistance (SVR)/high SvO2. 
 Altered skin perfusion 
 Decreased urine output 
 Hyperlactatemia (increased base deficit). 
Signs of organ dysfunction 
 Hypoxemia 
 Coagulation abnormalities 
 Altered mental status 
 Hyperglycemia 
 Thrombocytopenia, disseminated intravascular coagulation 
 Altered liver function (hyperbiblirubinemia) 
 Intolerance to feeding (altered gastrointestinal motility) 
Abbreviation; PCT, procalcitonin; CRP C-reactive protein; IL-6 interleukine -6; SVR systemic vascular 
resistance; SvO2 Mixed venous oxygen saturation 
(Reprinted with permission from, corresponding author Prof. Jean-Louis Vincent). Adapted from, 
Vincent, J. L., Martinez, E. O., & Silva, E. (2009). Evolving Concepts in Sepsis Definitions. Crit Care 
Clin, 25, 665–675. 
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1.2 Pathophysiology of sepsis  
Historically, mediators such as cytokines e.g. tumor necrosis factor [TNF], interleukin 
[IL]-1 were considered most important in the pathophysiology of sepsis. This view was 
derived from experiments indicating that when such mediators were injected into 
animals or healthy volunteers a syndrome with many features of septic shock developed 
(Beutler, 1993). However, in the mid 1990s it became evident that this view of the 
pathophysiological alterations in sepsis was clearly too narrow and in reality there is a 
very complex interaction between microbial pathogen, immunocompetent cells, their 
mediators, endothelial cells and the coagulation system. 
Sepsis remains a critical problem with significant morbidity and mortality even in the 
modern era of critical care management. Multiple derangements exist in sepsis 
involving several different organs and systems, although controversies exist over their 
individual contribution to the disease process. Septic patients have substantial, life-
threatening alterations in their coagulation system. Previously, it was believed that 
sepsis merely represented an exaggerated, hyperinflammatory response with patients 
dying from inflammation induced organ injury. Data that are more recent indicate that 
substantial heterogeneity exists in septic patients’ inflammatory response, with some 
appearing immuno-stimulated, whereas others appear suppressed.  
Cellular changes continue the theme of heterogeneity. Some cells work too well such as 
neutrophils that remain activated for an extended time. Other cellular changes become 
accelerated in a detrimental fashion including lymphocyte apoptosis.  
Metabolic changes are clearly present, requiring close and individualized monitoring. At 
this point in time, the literature richly illustrates that no single mediator/system/ 
pathway/pathogen drives the pathophysiology of sepsis (Daniel et al., 2007). 
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Progress in the molecular mechanisms of sepsis has provided a new level of 
understanding into the complex clinical course of human sepsis. Appropriate design of 
clinical trials in patients with sepsis needs to account for genetic and environmental 
variations found in patients and potential microbial pathogens. It has become evident 
that patients with sepsis are a very heterogeneous population. Certainly not every 
patient who meets the clinical criteria for severe sepsis is an ideal candidate for a 
clinical trial with a new therapeutic agent. It is now clear that there is no ‘magic bullet’ 
for sepsis, and it is likely there will never be one because most patients with sepsis have 
some form of underlying morbidity that predisposes them to develop sepsis.  
One of the major conclusions derived from the ‘first generation’ of sepsis trials was the 
insight that patients with a high risk of dying during their septic episode because of their 
underlying illness should not have been enrolled into clinical trials. Such patients are 
unlikely to have any benefit from any therapy. In clinical trials, these patients introduce 
statistical ‘noise’, making it more difficult to detect a beneficial ‘signal’ of the 
compound under investigation, especially if this signal (effect) is weak (Eidelman et al., 
1994).  
    The application of these new insights into the pathophysiology of sepsis together with 
optimized patient selection and conduct of clinical trials eventually yielded the long-
sought-after progress in sepsis therapy (Glück & Opal et al., 2004). 
 
1.2.1 Dysregulated coagulation 
Normal hemostasis exists as a finely tuned balance where the blood typically remains 
liquid to allow free flow within the vessels yet clots appropriately to control bleeding. 
Under normal conditions, the clotting cascade is extremely complex (Esmon, 2006). 
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During inflammatory situations such as sepsis, significant alterations occur at multiple 
levels within both the coagulation system and the cells that regulate this system (Esmon, 
2005). Septic patients frequently manifest disseminated intravascular coagulation (DIC) 
with consumption of platelets and prolongation of clotting times. In addition, the altered 
hemostasis allows blood to clot when it should not be clogging blood vessels and 
reducing blood flow. Because the liver produces fixed quantities of procoagulant 
factors, and the bone marrow releases a defined number of white blood cells into the 
circulation, local effects modulate the systemic coagulopathy. In other words, although 
the coagulopathy is systemic, the bleeding typically occurs in select sites, where 
dysfunctional vasculature provides the necessary environment for bleeding to occur at 
that site. The interaction between the clotting system, circulating white blood cells and 
platelets, and the endothelium adds another layer to an already multifaceted picture. 
Although several of these abnormalities have been documented in septic patients, the 
underlying cause of the coagulopathy almost certainly remains multifactorial. 
Abnormalities in the coagulation system resulting from systemic illnesses, which cause 
local disturbances in hemostasis and the thrombotic potential of cancer patients, have 
been described since the time of Virchow (Fink, 2001). Virchow’s classic triad consists 
of changes in coagulability, endothelial cell injury, and abnormal blood flow. In septic 
patients, all three of these classic alterations are present and culminate in reduced blood 
flow to vital organs. Septic patients frequently have poor tissue perfusion in addition to 
inappropriate use of oxygen with resulting cytopathic hypoxia (Fink, 2001). The 
coagulation abnormalities in septic patients are profound and have led to a successful, 
food and drug administration-approved therapeutic intervention: activated protein c 
(APC, marketed under the name Xigris; Eli Lilly & Co., Indianapolis, IN). (Fink et al., 
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2001). The approval of APC was controversial, with half of the food and drug 
administration panel voting to require a confirmatory trial (Eichacker et al., 2006). 
The successful clinical trials with APC for the treatment of sepsis were initiated 
following studies in the baboon model of Escherichia coli sepsis (Esmon et al., 1987). 
There are very few compounds that have successfully made the transition from 
preclinical sepsis trials to a viable therapeutic option. Approval of APC for the 
treatment of septic patients clearly demonstrates that alterations in the coagulation 
system are important in sepsis mortality. Despite the success, the mechanism of action, 
beyond the coagulation system, has not been fully defined. It has been postulated that 
APC has anti-inflammatory properties that help to explain the beneficial effects. 
However, the question of whether excessive inflammation plays a critical role in sepsis 
mortality has yet to be definitively answered. Although APC improves survival in 
patients with severe sepsis, it is clearly not a panacea for all patients. Analysis of the 
initial data showed that the most beneficial effects were observed in patients with the 
worst prognosis. Follow- up studies demonstrated that patients at low risk for death had 
no improvement in survival and had a significantly increased risk of bleeding if treated 
with activated protein C (Jimenez et al., 2002; Segal, 2002; Abraham et al., 2005; Gullo 
et al., 2005; Heper et al., 2006). 
 
1.2.2 Aberrant mediator production 
The inflammatory response represents an important, central component of sepsis 
because elements of the response drive the physiological alterations that become 
manifest as the systemic inflammatory response syndrome. An appropriate 
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inflammatory response eliminates the invading microorganisms without causing damage 
to tissues, organs, or other systems, (Figure 1.3). 
 
 
Figure 1.3: Control of coagulation in normal and inflamed vasculature. Top panel: 
normal function. Vascular injury, indicated on the lower portion of the blood vessel wall, initiates 
prothrombin (Pro) activation, which subsequently induces thrombin (T) formation. Prothrombin 
activation involves the formation of complexes between factor Va and factor Xa. Thrombin then binds to 
thrombomodulin (TM) on the luminal side of the endothelial cell wall, and the thrombin-TM complex 
converts protein C to APC. APC then binds to protein S (S) on endothelial cell surfaces. The complex 
composed of protein S and APC then converts factor Va into an inactive complex (VI). Protein S and APC 
also interact with the endothelial cell protein C receptor (EPCR). Bottom panel: after inflammation. 
During inflammation, specific mediators cause the disappearance of thrombomodulin from the 
endothelial cell surface. The endothelial cell leukocyte adhesion molecules P-selectin and E-selectin are 
synthesized and expressed on the surfaces of endothelial cells or platelets. Tissue factor (TF) is expressed 
on monocytes where it binds to factor VIIa. The TF-VIIa complex converts factor X to factor Xa, which 
then complexes with factor Va to generate thrombin from prothrombin. Very little APC is formed, and 
that which is formed does not function well because of low levels of protein S. Consequently, factor Va is 
not activated, and the prothrombin activation complexes are stabilized. Modified from Br J Haematol, 
131, Esmon CT, The interactions between inflammation and coagulation, 417–430, Copyright (2005), 
(Reprinted with permission from corresponding author. Daniel, G. R. (2007). Biological Perspectives 
Pathophysiology of Sepsis. BAm J Pathol, 170, 1435–1444) 
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1.2.2.1 Hyperinflammatory response 
Several years ago, many basic science investigators and clinicians believed that the 
problem of sepsis was directly related to the exuberant production of proinflammatory 
molecules. The problem seemed rather simple: inflammation was excessive. The 
solution was easy: blunt inflammation, and save lives. This concept was driven by four 
pieces of information. First, septic patients with increased levels of specific mediators 
such as tumor necrosis factor (TNF) are at increased risk for death (Waage et al., 1987). 
Second, injection of TNF molecules into experimental animals results in widespread 
inflammatory alterations (Remick et al., 1987) and tissue injury (Tracey et al., 1986) 
similar to that observed in septic patients. Third, experimental animals injected with 
lethal doses of endotoxin display elevated levels of the same mediators. Finally, 
inhibition of these specific mediators improves survival in endotoxin shock models 
(Beutler et al., 1985; Abraham, Glauser et al., 1997; Abraham, Laterre et al., 2001; 
Cohen, 1999; Gordon et al., 2004). Together, these observations launched a series of 
clinical trials aimed at blocking TNF or interleukin (IL)-1. 
  Although these individual trials did not show significant or dramatic improvements in 
survival, a meta-analysis of all TNF inhibitors did demonstrate overall improvement 
(Marshall, 2003). Despite these failed endeavors’, exploration of new mediators of 
organ injury should still be explored. Among the potential candidates is high mobility 
group (Wang et al., 1999; Baron, 2006) triggering receptor expressed on myeloid cells 
(TREM), (Gibot et al., 2006) and vascular endothelial growth factor (Rodrick et al., 
1986). Another work mentioned the role of the complement system in sepsis, 
undoubtedly providing another fruitful area for investigation (Niederbichler et al., 
2006). 
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 A frequent explanation put forth for the previous inhibitor trial failures was that the 
anti-inflammatory agents were not administered quickly enough. The classic endotoxin 
model of “sepsis” drove much of this thinking. In this model, lethal doses of endotoxin 
are injected intraperitoneally or intravenously into an experimental animal. Endotoxin 
induces a massive, rapid release of several proinflammatory molecules, including 
cytokines in both humans and experimental animals (Copeland et al., 2005). However, 
subsequent work has shown that models of sepsis that more closely reproduce the 
clinical situation, such as caused by cecal ligation and puncture, induce a 
proinflammatory response that is substantially lower in magnitude and longer in 
duration than that observed after acute exposure to endotoxin (Remick et al., 2000; 
Osuchowski et al., 2006). In addition, human clinical trials aimed at giving global 
immunosuppression with high-dose glucocorticoids failed to yield any improvement in 
survival. Although the cecal ligation and puncture model of sepsis has become widely 
used, it may not represent the best preclinical model because most septic patients have a 
pulmonary source of infection (pneumonia) rather than peritoneal. Controversy remains 
about the best animal model for the study of sepsis (Buras et al., 2005). 
 In traditional thinking, a mediator must be elevated and detectable to be implicated in 
the pathogenesis of disease. In septic patients with poor survival, TNF was elevated, and 
this provided a portion of the rationale on why it should be blocked. However, it must 
be borne in mind that cytokines may have significant effects at the local level such that 
detectable plasma levels may not be necessary for the cytokine blockade to be effective. 
This was shown dramatically in a recent clinical trial of neonatal-onset multisystem 
inflammatory disease where children treated with the IL-1 receptor antagonist 
demonstrated a remarkable improvement in both objective and subjective criteria 
(Goldbach-Mansky et al., 2006). This dramatic improvement occurred even though IL-1 
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was not detectable in the plasma. As one index of improvement, IL-6 levels were 
significantly decreased with IL-1 receptor antagonist treatment. 
 
1.2.2.2 Blunted inflammatory response 
Another viewpoint would argue that septic patients failed to control the bacterial 
infection and died as a result of immunosuppression rather than immunostimulation. 
Recent work has shown that intensive care unit patients have reduced production of 
both TNF and IL-6 in response to endotoxin stimulation (Heagy et al., 2000; Heagy et 
al., 2003). Another study demonstrated that although TNF was reduced, IL-10 
production was not impaired in patients with sepsis (Rigato et al., 2003). These studies 
would indicate that the proinflammatory response could not be initiated, whereas the 
anti-inflammatory response continued unabated, producing the equivalent of a blunted 
inflammatory response. Patients with severe burns and sepsis exhibit defects in their T 
lymphocytes because the cells fail to proliferate in response to mitogenic stimuli and 
also fail to produce IL-2 or -12 (Rodrick et al., 1986; O’Sullivan et al., 1995). Because 
blocking the inflammatory response with specific inhibitors was not tremendously 
effective, the possibility was raised that the patients required immunostimulation. 
However, in the clinical trial using granulocyte colony-stimulating factor (G-CSF) to 
treat 701 patients with pneumonia and severe sepsis, there was no improvement in 
survival (Root et al., 2003). In a smaller study with 58 patients, granulocyte 
macrophage colony-stimulating factor (GM-CSF) also did not improve survival but did 
decrease length of hospitalization and improve other clinical parameters (Orozco et al., 
2006; Carr et al., 2009). The blunted monocyte response observed in septic patients has 
been reversed with interferon, and systemic therapy successfully cleared sepsis in eight 
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of nine patients (Do¨cke et al., 1997). A larger clinical trial with 416 trauma patients 
indicated that interferon therapy did not reduce infections or overall mortality but did 
reduce deaths due to infections (Dries et al., 1994). 
 
1.2.2.3 Unknown inflammatory response 
The previous data would indicate that the inflammatory response in septic patients is 
complex and not as neatly defined as enhanced or decreased. Because of this 
heterogeneous response, some patients will benefit from blunting their inflammation, 
whereas others would be better served by augmenting their inflammatory response. 
Tailoring the therapy to the individual patient occurs with many diseases, and sepsis 
should not be an exception. Work with the preclinical model of sepsis has indicated that 
blunting inflammation only improves survival in those animals at a high risk of dying 
(Remick et al., 2003). Clinical evidence favoring a tailored response comes from sepsis 
trials demonstrating that low-dose glucocorticoid therapy is most effective in those 
patients with an impaired adrenal response (Annane et al., 2002). Roger Bone observed, 
“We should spend more time learning how to achieve an accurate diagnosis and less 
time searching for a magic bullet.” (Bone et al., 1996). In this context, different plasma 
markers have been proposed as diagnostic markers for the presence of sepsis as well as 
the severity of sepsis. These molecules may not actually participate in the cell or organ 
injury but may serve as markers for the presence and severity of sepsis. It must be 
acknowledged that controversy exists in this area. Some investigators believe that IL-6 
serves as a marker of injury (Remick et al., 2002); whereas others believe, that IL-6 
may be responsible for the altered pathophysiology. Measuring plasma levels of 
cytokines is probably not sufficient to determine whether a patient or experimental 
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animal is hyperinflammatory or hypoinflammatory. If only the proinflammatory 
mediators are measured, then the patient will appear hyperinflammatory. Conversely, if 
only cytokine antagonists or anti-inflammatory mediators are measured, a person 
appears to be hypoinflammatory. In fact, both proinflammatory and anti-inflammatory 
mediators may be circulating at the same time in the plasma. Better methods for 
determining the precise immunological status may be achieved via either a multiplex 
format for cytokine measurements (Marti et al., 2003; Knight et al., 2004; Kumar, 
Sudhir et al., 2009) or an evaluation of cellular function. 
 
1.2.3 Cellular dysfunction 
Many cellular aspects become dysfunctional in sepsis and may be characterized as 
either excessive activation or depressed function. Excessive activation refers to cells 
that are primed such that they respond in a very vigorous manner to a second stimulus. 
An example of excessive activation would be neutrophils generating excess toxic 
products that cause damage to nearby cells (Weiss, 1989). An example of depressed 
function would be neutrophil failure to phagocytize and clear invading pathogens. One 
of the current areas of active investigation concerning cellular function is the induction 
of cellular apoptosis or necrosis. The signaling mechanisms and molecules that induce 
apoptosis are currently being described in great detail by a number of investigators. One 
must carefully evaluate the literature with regard to apoptosis because some detection 
methodologies suffer from a high rate of false-positive reactions with subsequent 
controversy concerning the findings (Grassme et al., 2001; Hotchkiss et al., 2001). 
Apoptosis and necrosis in the field of sepsis have been reviewed quite nicely in the 
recent past (Oberholzer et al., 2001; Wesche et al., 2005). Apoptosis may contribute to 
21 
 
the pathogenesis of sepsis by delayed removal of those cells that should be removed (i.e. 
neutrophils) and early removal of those cells that should not be removed (i.e. 
lymphocytes). 
 
1.2.3.1 Lymphocyte apoptosis 
Lymphocytes are critical cells in the response to sepsis, and the interactions between the 
innate and adaptive immune system are becoming increasingly important. Pioneering 
studies by Hotchkiss et al., (1999) have defined that septic patients have significant 
apoptosis of lymphocytes.  
These apoptotic lymphocytes were observed in virtually all lymphoid organs including 
the obvious locations, such as the spleen and thymus, but also in the gastric associated 
lymphatic tissue and essentially, wherever collections of lymphocytes exist. These 
murine experiments were extended in a very interesting study when these investigators 
performed rapid autopsies in the intensive care unit on patients who died from sepsis 
(Hotchkiss et al., 1999). It was necessary to perform the autopsies rapidly to collect 
tissue that did not display substantial post-mortem autolysis. Lymphocyte apoptosis 
may be the cause of the reduced lymphocyte function in septic patients previously 
described (failure to produce cytokines). In septic patients, there is a combination of 
apoptotic and necrotic cell death. The importance of apoptosis in the pathophysiology of 
sepsis has been demonstrated in multiple studies (Wesche et al., 2005). It has been 
shown transfer of apoptotic splenocytes will worsen survival in a mouse model of 
sepsis, whereas transfer of necrotic splenocytes improves survival (Hotchkiss et al., 
2003).  
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1.2.3.2 Neutrophil hyperactivity 
Neutrophils are critical components of the innate immune response to infectious 
challenges. Neutropenic patients, regardless of the cause of the neutropenia, and patients 
with neutrophil dysfunction are at increased risk for the development of infectious 
complications (Lekstrom-Himes et al., 2000). The appropriate neutrophil response will 
help the patient to eradicate an infectious focus. The difficulty lies in attempting to 
define an appropriate response versus a hyperactive response (Brown et al., 2006; Koch 
& Zacharowski, 2009), as illustrated in Figure 1.4. Patients who have suffered traumatic 
injury are at increased risk for the development of multisystem organ failure, and 
neutrophils recovered from such patients demonstrate increased chemotactic responses 
to CXC chemokines (Bhatia et al., 2005). However, neutrophils isolated from septic 
patients demonstrate decreased chemotaxis toward IL-8 and depressed expression of 
CXCR2 (Chishti et al., 2004). These results were further explored in an article showing 
that high CXCR2 function correlates with the development of organ injury, i.e., acute 
respiratory distress syndrome, whereas low function predisposes to pneumonia and 
sepsis (Adams et al., 2001). These studies aptly demonstrate the heterogeneity of the 
septic response in that some patients have an excessive response, whereas others have a 
blunted response. Modulating the recruitment of neutrophils to the site of inflammation 
has potential benefits, but this should be via specific modulation rather than global 
inhibition of neutrophil function. Recently, classes of immunomodulatory compounds 
termed pepducins, which are cell-penetrating lipopeptides, have been used to target 
CXC chemokine receptors (Kaneider et al., 2005). These compounds were able to block 
neutrophil chemotaxis to CXC chemokines without affecting neutrophil responses to 
other stimulants such as the formyl peptides. These compounds were used in the murine 
model of cecal ligation and puncture-induced sepsis, where they were able to 
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significantly improve survival. Another significant issue concerns inappropriate 
apoptosis of neutrophils in the septic patients. Neutrophils in the circulation typically 
have a very short lifespan of approximately 24 hours. However, patients with sepsis 
have a delay in their neutrophil apoptosis, causing them to persist longer in the 
bloodstream. This is due to prolonged activation of nuclear factor B and reduced 
caspase 3 levels (Taneja et al., 2004). As a result, the septic patient has increased 
numbers of activated cells with the potential to cause organ injury. However, it must be 
borne in mind that these activated neutrophils are also the precise defenders that are 
critical in the innate immune response to clear an infection (Smith, 1994; Brunialti et 
al., 2006; Zhu & Qu, 2007; Salomao et al., 2009). 
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Figure 1.4: Proposed model for dysregulation of neutrophil recruitment to 
bacterial infection in non-pulmonary tissue under normal conditions (left) and in sepsis (right). 
Colony stimulating factors [granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage 
colony-stimulating factor (GM-CSF)] induce the release of neutrophils from the bone marrow. Under 
normal conditions, large numbers of the peripheral blood neutrophils enter sites of bacterial infection by 
first adhering to activated endothelial cells and then migrating along a gradient of chemotactic factors. 
These chemotactic factors are produced at the local site of infection. Neutrophils use Toll-like receptors 
(TLR-2 or TLR-4) to interact with pathogen-associated molecular patterns on bacteria to phagocytize and 
eliminate the pathogens. In contrast, neutrophils from septic patients have increased expression of surface 
integrins, which promote firm adhesion to endothelial cells. As a consequence, the neutrophils remain 
bound more tightly to the endothelial cells and fail to migrate appropriately into the site of the bacterial 
infection. (Reprinted with permission from corresponding author. Daniel, G. R. (2007). Biological 
Perspectives Pathophysiology of Sepsis. BAm J Pathol, 170, 1435–1444) 
 
 
1.2.3.3 Endothelial cell failure and apoptosis in other cells 
Endothelial cells reside at the critical interface between the blood and tissue. Intact 
endothelial cells exhibit anticoagulant properties through elaboration of anticoagulant 
molecules such as protein C. These cells also serve as a barrier between blood products 
and procoagulant molecules, such as heparin, residing in the extracellular matrix. 
Endothelial disruption comes about because of increased expression of adhesion 
